Top 15 der gesamten Suchanfragen der letzten 7 Tage

Aktie

ISIN: US23283M1018 WKN: A0YHA5 SYM: 296 Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,2540

EUR

+2,42 %

+0,0060 EUR

Letzter Kurs 10.07.25 Stuttgart

Cytodyn Aktie kaufen

Geldkurs

10.07.25

0,2640

EUR

13.500 STK

Briefkurs

10.07.25

0,2960

EUR

13.500 STK

Neueste Nachrichten

CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab 01.07.25 · globenewswire · Cytodyn
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer 24.06.25 · globenewswire · Cytodyn
CytoDyn Releases ESMO Breast Cancer Meeting Poster 15.05.25 · globenewswire · Cytodyn
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors 13.05.25 · globenewswire · Cytodyn
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer 06.05.25 · globenewswire · Cytodyn
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany 29.04.25 · globenewswire · Cytodyn
March 2025 Letter to Shareholders 18.03.25 · globenewswire · Cytodyn
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab 24.02.25 · globenewswire · Cytodyn
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories 06.02.25 · globenewswire · Cytodyn
December 2024 Letter to Shareholders 17.12.24 · globenewswire · Cytodyn
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology 25.11.24 · globenewswire · Cytodyn
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial 04.11.24 · globenewswire · Cytodyn

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer 160 Leser
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer ... 144 Leser

CytoDyn Engages Leading CRO For Phase II Inflammation Trial 760 Leser
September 2024 Letter to Shareholders 396 Leser
December 2024 Letter to Shareholders 316 Leser
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with ... 304 Leser
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of ... 272 Leser
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab 256 Leser
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology 244 Leser
March 2025 Letter to Shareholders 224 Leser
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories 216 Leser
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development 212 Leser